MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-06-0001108
Danopharm Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹108.78 Cr
▼ 7% YoY
Net profit · FY 2025
₹6.52 Cr
Net margin 6%
EBITDA · FY 2025
₹12.38 Cr
EBITDA margin 11.4%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹2 Cr
Issued & subscribed
Open charges
₹21.18 Cr
Satisfied ₹11.25 Cr
Company age
17 yrs
Est. 2009
Employees · EPFO
85
Provident fund records
About Danopharm Private Limited
Data last updated:
Danopharm Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Synergy Health Sciences Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 15 January 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24100MH2009PTC189592. Its GSTIN is 24AADCD0819L2ZR (Gujarat). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹2 Cr. It was formerly known as Danopharm Chemicals Limited. It is led by directors including Jayanta Badalchandra Das and Kamlesh Badal Das.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Unit No 117 Ravi Kiran 1st Floor Near Monginis Off New Link Road Andheri(West), Mumbai, Maharashtra, India – 400053.
As per the financials filed for FY 2025, the company reported a revenue of ₹108.78 Cr, a decline of 7% compared to the previous year. For the same year it recorded a net profit of ₹6.52 Cr (net margin 6%) and EBITDA of ₹12.38 Cr (EBITDA margin 11.4%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 11% over five years.
The company has about 85 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Danopharm Chemicals. As per MCA filings, the company has open charges of ₹21.18 Cr and satisfied charges of ₹11.25 Cr on record. Court records list 3 cases involving the company, including 1 filed by the company and 2 filed against it. The company has 6 deals on record (4 funding rounds, 2 secondary share transfers), with disclosed funding of ₹5.19 Cr; the latest was in November 2012. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Archimedis Laboratories Private Limited with revenue of ₹114.19 Cr. The company has 8 MSME Form 1 returns on record between 2019 and 2023, listing 992 overdue payments to 85 micro and small suppliers.
Danopharm Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-06-0001108). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website danopharm.com.
Company Details of Danopharm Private Limited
CIN U24100MH2009PTC189592
Registration Number 189592
Incorporation Date 15 January 2009
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Parent Company Synergy Health Sciences Private Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-06-0001108
Name History of Danopharm Private Limited
Danopharm has undergone 2 name changes throughout its history. The company was previously known as Danopharm Chemicals Limited, and Danopharm Private Limited. The current legal name is Danopharm Private Limited.
| Company Name | Status |
|---|---|
| Danopharm Private Limited | Current |
| Danopharm Chemicals Limited | Previous |
Key People
Jayanta Badalchandra Das Director Kamlesh Badal Das Director Satish Prabhakar Nachane Director Recognitions & Rankings of Danopharm
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressUnit No 117 Ravi Kiran 1st Floor Near Monginis Off New Link Road Andheri(West), Mumbai, Maharashtra, India – 400053
- IndustryPharma, API Manufacturers
Comprehensive company report
Danopharm Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Danopharm Private Limited
Danopharm operates one associated brand: Danopharm Chemicals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures high-quality bulk drugs and pharmaceutical intermediates. | danopharm.com |
Business Activity of Danopharm Private Limited
The main business activity of Danopharm is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Danopharm Private Limited FY 2024 filings available
Danopharm Private Limited reported revenue of ₹108.78 Cr (down 7% YoY) for FY 2025.
Revenue · FY 2025
₹108.78 Cr ▼ 7%
Net profit · FY 2025
₹6.52 Cr margin 6%
EBITDA · FY 2025
₹12.38 Cr margin 11.4%
Compounded Annual Growth Rate (CAGR) of Danopharm Private Limited
Revenue CAGR growth
1 year
▼ 7%
3 years · compounded
▼ 6%
5 years · compounded
▲ 11%
EBITDA CAGR growth
1 year
▼ 10%
3 years · compounded
▼ 6%
5 years · compounded
▲ 13%
Revenue fell 7% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 11%. EBITDA fell 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Danopharm Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹12.38 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹6.52 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Danopharm Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Danopharm are in the company report.
Premium access
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Danopharm Private Limited
Danopharm has 8 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jayanta Badalchandra Das Also directs: Ankleshwar Waste Management Association | Director | 15 Jan 2009 | 17 Years 9 Months | Current |
| Kamlesh Badal Das | Director | 15 Jan 2009 | 17 Years 9 Months | Current |
| Satish Prabhakar Nachane | Director | 03 Sep 2009 | 17 Years 1 Months | Current |
| Ramesh Eknath Jadhav Also directs: Synergy Health Sciences Private Limited | Director | 16 Mar 2010 | 16 Years 7 Months | Current |
| Sabu Daniel Also directs: Synergy Health Sciences Private Limited | Director | 16 Mar 2010 | 16 Years 7 Months | Current |
| Kashinath Badal Das | Director | 15 Jan 2009 | 17 Years 9 Months | Current |
Showing 6 of 8 current directors. View all directors
Peer Comparison of Danopharm Private Limited
Danopharm Private Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Archimedis Laboratories Private Limited | ₹114.19 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Hyderabad, Telangana, India |
| Glochem Industries Private Limited | ₹113.55 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Hyderabad, Telangana, India |
| Venkar Chemicals Private Limited | ₹112.58 Cr (FY 2024) | •••• | •••• | 61.0% | •••• | Hyderabad, Telangana, India |
| Farmson Pharmaceutical Gujarat Private Limited | ₹111.99 Cr (FY 2025) | •••• | •••• | 52.0% | •••• | Vadodara, Gujarat, India |
| Bakul Pharma Private Limited | ₹110.31 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Mumbai, Maharashtra, India |
| Danopharm Private Limited this company | ₹108.78 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Mumbai, Maharashtra, India |
| Srisaichandana Api Private Limited | ₹108.36 Cr (FY 2025) | •••• | •••• | 33.0% | •••• | Visakhapatnam, Andhra Pradesh, India |
| Almelo Private Limited | ₹108.05 Cr (FY 2024) | •••• | •••• | 22.0% | •••• | Hyderabad, Telangana, India |
| Virdev Intermediates Private Limited | ₹107.72 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | Surat, Gujarat, India |
| Panchsheel Organics Limited Listed | ₹107.68 Cr (FY 2024) | •••• | •••• | 3.0% | •••• | Indore, Madhya Pradesh, India |
| Patel Chem Specialities Limited | ₹105.55 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | Ahmedabad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Danopharm by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Danopharm Private Limited
Danopharm Private Limited is audited by P N HATHI & Co. for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P N HATHI & Co. | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Danopharm Private Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Danopharm Private Limited
Open charges
₹21.18 Cr
Satisfied charges
₹11.25 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2011 | State Bank of India | ₹21.18 Cr | Open |
| 15 Sep 2009 | United Bank of India | ₹11.25 Cr | Satisfied |
Total charge records: 2 View all charges
Deals & Funding of Danopharm Private Limited
Danopharm Private Limited has 6 deals on record (4 funding rounds, 2 secondary share transfers), with disclosed funding of ₹5.19 Cr; the latest was in November 2012.
Total deals
6
Funding rounds
4
Secondary share transfers
2
Disclosed funding
₹5.19 Cr
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2012 | Funding round | ₹2 Cr | Investors: Synergy Health Sciences Private Limited , 3 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: Synergy Health Sciences Private Limited Seller: 4 individuals |
| Jun 2011 | Funding round | ₹2.04 Cr | Investors: Synergy Health Sciences Private Limited , 3 individuals |
| Mar 2010 | Secondary share transfer | Undisclosed | Buyer: Synergy Health Sciences Private Limited Seller: 4 individuals |
| Oct 2009 | Funding round | ₹40 Lakh | Investors: Synergy Health Sciences Private Limited , 3 individuals |
Premium access
Full deal history
All 6 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Danopharm Private Limited
Danopharm Private Limited has 3 court cases on record: 1 filed by Danopharm, 2 filed against it. All cases are disposed. Status as checked between 02 Oct 2026 and 04 Oct 2026.
Total cases
3
Filed by the company
1
Filed against the company
2
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 2 | 0 |
| District courts | 1 | 0 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thane, Maharashtra | Court case (Sum.Civ.Suit) | Filed by the company against an individual | Disposed |
| Bombay High Court | Company petition | Filed against the company by Jiangsu Guotai International Group Winsun Import and Export Co Ltd | Disposed |
| Bombay High Court | Company petition | Filed against the company by Jaingsu Guotai International Group Hua Tai Import and Export Co. Ltd | Disposed |
Premium access
Full case history
All 3 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Danopharm Private Limited
Danopharm Private Limited has 8 MSME Form 1 returns on record between 2019 and 2023, listing 992 overdue payments to 85 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 85)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ganesh Cables | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Precitech Laboratories Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Mrugal Enterprise | •••• | •••• | •••• |
Premium access
Full MSME payment history
Every supplier, amount and due date from all 8 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Employees and EPFO Compliance at Danopharm Private Limited
Danopharm Private Limited has a workforce of 85 employees as of Apr 04, 2024.
Employee count
85
Active EPFO establishments
1
Employee growth
25%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Danopharm Private Limited
Danopharm Private Limited has 10 board changes on record since 2009: 8 appointments and 2 cessations. The latest: Mehul Satish Nachane ceased to be Additional Director on 31 Jul 2010.
AGM
Danopharm Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Danopharm Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Charges
A charge with State Bank Of India of Rs. 21.18 Cr registered on 21 Jul 2011 with Charge ID 10302455 was modified on 03 Aug 2023.
Charges
A charge registered on 15 Sep 2009 via Charge ID 10177240 with United Bank Of India was fully satisfied on 15 Jun 2012.
Charges
A charge with State Bank Of India amounted to Rs. 21.18 Cr with Charge ID 10302455 was registered on 21 Jul 2011.
Charges
A charge with United Bank Of India of Rs. 11.25 Cr registered on 15 Sep 2009 with Charge ID 10177240 was modified on 23 Sep 2010.
Ceased
Mehul Satish Nachane ceased to be Additional Director.
Ceased
Satish Prabhakar Nachane ceased to be Additional Director.
Appointed
Ramesh Eknath Jadhav was appointed as Director.
Appointed
Sabu Daniel was appointed as Director.
Charges
A charge with United Bank Of India amounted to Rs. 11.25 Cr with Charge ID 10177240 was registered on 15 Sep 2009.
Appointed
Mehul Satish Nachane was appointed as Director.
6 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Danopharm Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Danopharm Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Danopharm Private Limited
Danopharm has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AADCD0819L2ZR | Gujarat | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Danopharm Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Danopharm Private Limited
Danopharm is an active private limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 15 January 2009 (17+ years old) and is registered under CIN U24100MH2009PTC189592.
Danopharm reported revenue of ₹108.78 Cr for FY 2025 (down 7% YoY).
Danopharm has 8 current directors:
- Jayanta Badalchandra Das - Director
- Kamlesh Badal Das - Director
- Satish Prabhakar Nachane - Director
- Ramesh Eknath Jadhav - Director
- Sabu Daniel - Director
- Kashinath Badal Das - Director
- Mehul Satish Nachane - Director
- Bimlesh Badalchandra Das - Director
Danopharm reported a net profit of ₹6.52 Cr (net margin 6%) and EBITDA of ₹12.38 Cr (EBITDA margin 11.4%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Danopharm is -6% over three years and 11% over five years. In the latest year (FY 2025) revenue fell 7%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Danopharm is 24AADCD0819L2ZR, registered in Gujarat. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Danopharm is U24100MH2009PTC189592. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Danopharm has 3 court cases on record: 1 filed by the company and 2 filed against it. Most are in the high courts.
Danopharm was incorporated on 15 January 2009, making it 17+ years old. It is registered with the Registrar of Companies, Mumbai.
Danopharm has 6 deals on record (4 funding rounds, 2 secondary share transfers), with disclosed funding of ₹5.19 Cr; the latest was in November 2012.
The peers of Danopharm by revenue are Archimedis Laboratories Private Limited, Glochem Industries Private Limited, Venkar Chemicals Private Limited, Farmson Pharmaceutical Gujarat Private Limited, Bakul Pharma Private Limited and 5 more, all in the Pharma industry (API Manufacturers).
Mehul Satish Nachane ceased to be Additional Director on 31 Jul 2010. Satish Prabhakar Nachane ceased to be Additional Director on 31 Jul 2010. Ramesh Eknath Jadhav was appointed as Director on 16 Mar 2010. Danopharm has 10 board changes on record in total.